Evidence map›Paper›PMID 39452731›Full record

ReviewPathogens (Basel, Switzerland)2024

Hepatitis C in Children-An Asia-Pacific Concise Perspective.

Lynette Goh, Winita Hardikar

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. GenericWorld journal of hepatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lynette GohDepartment of Gastroenterology, Hepatology and Nutrition, KK Women's and Children's Hospital, Singapore 229899, Singapore.
Winita HardikarGastroenterology and Clinical Nutrition, The Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the discovery of hepatitis C virus (HCV) in 1989, we now have curative treatment options with direct-acting antiviral therapies. By increasing the rate of treatment and reducing transmission, the eradication of HCV is potentially achievable. Nonetheless, the feasibility and implementation of this goal remains challenging. This article sums up the approach to managing children with HCV in the Asia-Pacific region and lists some of the difficulties and complexities surrounding this issue.

Indexed as

Antiviral AgentsHepacivirusHepatitis CAsiaChildHumansPacific IslandsAntiviral AgentsAsia–Pacificdirect-acting antiviralshepatitis C

Identifiers

PMID39452731
PMCPMC11510634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.